.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
US Army
Farmers Insurance
Cerilliant
Harvard Business School
Queensland Health
Teva
Boehringer Ingelheim
Daiichi Sankyo
Healthtrust

Generated: September 21, 2017

DrugPatentWatch Database Preview

XERESE Drug Profile

« Back to Dashboard

Which patents cover Xerese, and when can generic versions of Xerese launch?

Xerese is a drug marketed by Valeant Bermuda and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-eight patent family members in thirty-six countries.

The generic ingredient in XERESE is acyclovir; hydrocortisone. There are fifty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acyclovir; hydrocortisone profile page.

Summary for Tradename: XERESE

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:XERESE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: XERESE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: XERESE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,337,324 Pharmaceutical combination► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XERESE

Country Document Number Estimated Expiration
Morocco23800► Subscribe
European Patent Office1419803► Subscribe
Taiwan589191► Subscribe
Argentina023705► Subscribe
Algeria1966► Subscribe
Australia1436400► Subscribe
Japan5420583► Subscribe
Portugal876146► Subscribe
Yugoslavia7296► Subscribe
European Patent Office1131104► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: XERESE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
2010 00009Denmark► Subscribe
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Julphar
US Department of Justice
Mallinckrodt
UBS
Queensland Health
Express Scripts
Daiichi Sankyo
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot